Functional ingredients manufacturer Beneo, and Wacker, a European chemical supplier of biotechnology solutions, are launching the human milk oligosaccharide (HMO) 2’-Fucosyllactose (2’-FL) globally. The ingredient is dubbed the predominant and most extensively studied HMO and will be available to the European market in the coming weeks. As an HMO, 2’-FL belongs to a structurally and biologically diverse group of complex indigestible carbohydrates, which are the third major component in breast milk following lactose and lipids.
